QNCX logo

Quince Therapeutics (QNCX) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

09 May 2019

Indexes:

Not included

Website:

http://www.quincetx.com

Description:

Quince Therapeutics (QNCX) is a biotechnology company focused on developing innovative therapies for rare diseases. They aim to improve patient outcomes through advanced drug discovery and development, targeting conditions with high unmet medical needs. Their research emphasizes precision medicine and personalized treatment approaches.

Key Details

Price

$1.97

Market Cap

$86.68 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$0.84

PE Ratio

-

Annual ROE

-36.89%

Annual Debt To Equity

0.16

Beta

-0.38

Events Calendar

Earnings

Next earnings date:

May 13, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 17, 2020
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

02 Jan '25 D. Boral Capital
Buy
18 Dec '24 Brookline Capital
Buy
14 Nov '24 D. Boral Capital
Buy
12 Nov '24 D. Boral Capital
Buy
07 Nov '24 Maxim Group
Buy
29 Oct '24 Rodman & Renshaw
Buy
22 Oct '24 EF Hutton
Buy
11 May '22 Credit Suisse
Underperform
09 Mar '22 HC Wainwright & Co.
Buy
28 Jan '22 Canaccord Genuity
Hold

Screeners with QNCX included

Small cap stocks
NASDAQ earnings calendar
Stocks above SMA 50
Stocks with low beta
Stocks above SMA 200
Stocks below analysts price target
Most recommended stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.97
QNCX price is $1.97

Price YTD Change

+0.51%
QNCX price is up +0.51% since January 1st

Price All-time High

$120.21
QNCX price is currently -98.36% below its historical high of $120.21

Price Analysts Target

$9.00
QNCX price is currently -78.11% lower than the consensus analysts' forecast

Market Cap

$86.68 M
QNCX market capitalization is $86.68 million

Beta

-0.38
QNCX beta is -0.38

200-day SMA

$1.05
QNCX price is currently +86.96% above its 200-day simple moving average

14-day RSI

55.90
QNCX 14-day relative strength index is 55.90

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Net Income 3-Year Change

+65.11%
QNCX annual net profit is up +65.11% over the past 3 years

Annual EPS 3-Year Change

+72.28%
QNCX annual earnings per share is up +72.28% over the past 3 years

Annual EPS Estimate

-$1.17
QNCX annual earnings per share is currently -28.21% lower than the consensus analysts' forecast

Annual Operating Profit

-$27.14 M
QNCX annual operaing income is -$27.14 million

Annual Operating Profit 3-Year Change

+69.95%
QNCX annual operaing income is up +69.95% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-36.89%
QNCX annual return on equity is -36.89%

Annual ROA

-18.69%
QNCX annual return on assets is -18.69%

Annual EBIT

-$27.14 M
QNCX annual earnings before interest & taxes is -$27.14 million

Annual EBITDA

-$26.82 M
QNCX annual earnings before interest, taxes, depreciation & amortization is -$26.82 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PB Ratio Sector Rank

54.83%
QNCX price to book ratio is higher than 54.83% of companies in Healthcare sector

Enterprise Value

$99.46 M
QNCX enterprise value is $99.46 million

Enterprise Value 1-Year Change

+146.6%
QNCX enterprise value is up +146.6% year-on-year

EV/EBITDA

-2.93
QNCX EV/EBITDA is -2.93

EV/EBITDA Sector Rank

32.44%
QNCX EV/EBITDA is higher than 32.44% of companies in Healthcare sector

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Debt To Equity Sector Rank

66.53%
QNCX annual debt to equity ratio is higher than 66.53% of companies in Healthcare sector

Annual Current Ratio

8.09
QNCX annual current ratio is 8.09

Annual Current Ratio Sector Rank

81.37%
QNCX annual current ratio is higher than 81.37% of companies in Healthcare sector

Annual Total Assets

$167.90 M
QNCX annual total assets is $167.90 million

Annual Current Assets

$77.44 M
QNCX annual total current assets is $77.44 million

Annual Total Liabilities

$82.82 M
QNCX annual total liabilities is $82.82 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+70.93%
QNCX annual cash flow from operations is up +70.93% over the past 3 years

Annual CFI 3-Year Change

-109.77%
QNCX annual cash flow from investing activities is down -109.77% over the past 3 years

Annual CFF 3-Year Change

-97.9%
QNCX annual cash flow from financing activities is down -97.9% over the past 3 years

Annual FCF

-$18.45 M
QNCX annual free cash flow is -$18.45 million

Annual FCF 3-Year Change

+70.76%
QNCX annual free cash flow is up +70.76% over the past 3 years

Institutional Ownership

Similar stocks

SY logo
So-Young International (SY)
BLUE logo
bluebird bio (BLUE)
CTMX logo
CytomX Therapeutics (CTMX)
Genelux (GNLX)
AVTX logo
Avalo Therapeutics (AVTX)
THTX logo
Theratechnologies (THTX)
VOR logo
Vor Biopharma (VOR)
RBOT logo
Vicarious Surgical (RBOT)
ANL logo
Adlai Nortye American Depositary Shares (ANL)
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
QNCX
businesswire.com11 November 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd Child Neurology Society (CNS) Annual Meeting of safety data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial. The objective of the data analysis was to.

Quince Therapeutics to Participate at Upcoming Investor Conferences
Quince Therapeutics to Participate at Upcoming Investor Conferences
Quince Therapeutics to Participate at Upcoming Investor Conferences
QNCX
https://www.businesswire.com/news/home/20241014846322/en/Quince-Therapeutics-to-Participate-at-Upcoming-Investor-Conferences/14 October 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences: 2024 Maxim Healthcare Virtual Summit – Quince's Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., will participate in a fireside chat on Thursday, October 17, 2024 beginning at 3.

Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
QNCX
Zacks Investment Research07 March 2024

Two microcap biotech stocks to consider for the science-challenged among us.

FAQ

  • What is the primary business of Quince Therapeutics?
  • What is the ticker symbol for Quince Therapeutics?
  • Does Quince Therapeutics pay dividends?
  • What sector is Quince Therapeutics in?
  • What industry is Quince Therapeutics in?
  • What country is Quince Therapeutics based in?
  • When did Quince Therapeutics go public?
  • Is Quince Therapeutics in the S&P 500?
  • Is Quince Therapeutics in the NASDAQ 100?
  • Is Quince Therapeutics in the Dow Jones?
  • When was Quince Therapeutics's last earnings report?
  • When does Quince Therapeutics report earnings?
  • Should I buy Quince Therapeutics stock now?

What is the primary business of Quince Therapeutics?

Quince Therapeutics (QNCX) is a biotechnology company focused on developing innovative therapies for rare diseases. They aim to improve patient outcomes through advanced drug discovery and development, targeting conditions with high unmet medical needs. Their research emphasizes precision medicine and personalized treatment approaches.

What is the ticker symbol for Quince Therapeutics?

The ticker symbol for Quince Therapeutics is NASDAQ:QNCX

Does Quince Therapeutics pay dividends?

No, Quince Therapeutics does not pay dividends

What sector is Quince Therapeutics in?

Quince Therapeutics is in the Healthcare sector

What industry is Quince Therapeutics in?

Quince Therapeutics is in the Biotechnology industry

What country is Quince Therapeutics based in?

Quince Therapeutics is headquartered in United States

When did Quince Therapeutics go public?

Quince Therapeutics's initial public offering (IPO) was on 09 May 2019

Is Quince Therapeutics in the S&P 500?

No, Quince Therapeutics is not included in the S&P 500 index

Is Quince Therapeutics in the NASDAQ 100?

No, Quince Therapeutics is not included in the NASDAQ 100 index

Is Quince Therapeutics in the Dow Jones?

No, Quince Therapeutics is not included in the Dow Jones index

When was Quince Therapeutics's last earnings report?

Quince Therapeutics's most recent earnings report was on 13 November 2024

When does Quince Therapeutics report earnings?

The next expected earnings date for Quince Therapeutics is 13 May 2025

Should I buy Quince Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions